Akebia raises another $41m for oral anemia drug
This article was originally published in Scrip
Executive Summary
Akebia Theraputics has raised $41m in a series C financing round to fund on-going development of its lead compound, the oral anemia pill AKB-6548, taking the drug into Phase IIb testing in patients with anemia associated with chronic kidney disease (CKD).